4-羟基赖氨酸 | 61475-87-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-羟基赖氨酸
• 英文名称: (2S,4R)-4-hydroxylysine
• 英文别名: (2S,4S)-4-hydroxylysine；(4R)-4-hydroxylysine；4-hydroxylysine；2,6-diamino-4-hydroxyhexanoic acid
• CAS: 61475-87-4
• 化学式: C₆H₁₄N₂O₃
• 分子量: 162.189
• InChiKey: ASYBZHICIMVQII-UHFFFAOYSA-N

物化性质

• 沸点：
  414.1±45.0 °C(Predicted)
• 密度：
  1.268±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  110
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  DL-赖氨酸 在 一氧化二氮 作用下， 生成 4-羟基赖氨酸
  参考文献：
  名称：

  Hydroxyl radical-induced cross-linking of thymine and lysine: Identification of the primary structure and mechanism

  摘要：

  Hydroxyl radical-induced formation of a cross-link of thymine (Thy) and lysine (Lys) in the gamma-radiolysis of N2O-saturated aqueous solution was studied. A Thy-Lys cross-link (I) of the formal structure that OH radical and 4-carbon-centered Lys radical added respectively to C(5) and C(6) positions of Thy was isolated by a preparative HPLC and identified by a FAB-HRMS. The primary cross-link I was dehydrated by treatment with HCl at 120 degrees C to yield the secondary structure (II) possessing a C(5)-C(6) double bond in the Thy moiety: the latter structure II was reported previously (Dizdaroglu, M.; Gajewski, E. Cancer Res. 1989, 49, 3463-3467). A pulse radiolysis study with a redox titration method indicated that 4-carbon centered Lys radical intermediate was of neutral redox reactivity in contrast to reducing reactivity of 5-hydroxy-5,6-dihydrothymin-6-yl radical intermediate. The cross-link I could be formed by a conventional radical recombination mechanism, but not by an ionic recombination mechanism involving a redox reaction between the radical intermediates. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00124-3

文献信息

• [EN] METHODS FOR SELECTIVELY MODIFYING AMINO ACIDS AND PRODUCTS MADE THEREBY<br/>[FR] PROCÉDÉS DE MODIFICATION SÉLECTIVE D'ACIDES AMINÉS ET PRODUITS FABRIQUÉS PAR CEUX-CI
  申请人：UNIV CALIFORNIA

  公开号：WO2021007127A1

  公开（公告）日：2021-01-14

  Disclosed herein are methods for the selective substitution of a hydrogen bonded to a carbon atom (e.g., a hydrogen of an aliphatic methylene group) of a compound, which comprise contacting the compound with a substituent in the presence of a BesD halogenase.

  本文披露了一种选择性替代化合物中与碳原子结合的氢（例如，脂肪族亚甲基基团的氢）的方法，包括在BesD卤素酶存在的情况下将化合物与取代基接触。
• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20020065248A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of Formula (I): 1 wherein A 1 is methylene, ethylene or propylene group and A 2 is N or CR 5 , or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及化合物的结构公式（I）：其中A1为亚甲基、乙烯基或丙烯基，A2为N或CR5，或其立体异构体形式、立体异构体混合物或药用盐形式，用作HCV NS3蛋白酶的抑制剂，以及包含相同化合物的药物组合物和诊断试剂盒，以及用于治疗病毒感染或作为测定标准或试剂的方法。
• Peptide inhibitors of hepatitis C virus NS3 protein
  申请人：——

  公开号：US20020177725A1

  公开（公告）日：2002-11-28

  This invention relates to a novel class of peptides having the Formula (I): 1 Which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

  本发明涉及一类新型肽的公式(I)：1，其作为丝氨酸蛋白酶抑制剂具有用途，更具体地作为丙型肝炎病毒（HCV）NS3蛋白酶抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗HCV感染的方法。
• Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20020123468A1

  公开（公告）日：2002-09-05

  The present invention relates to ketoamide and ketoester compounds of Formula (I): 1 wherein W is —NH— or —O—, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及公式（I）的酮酰胺和酮酯化合物：1其中W为-NH-或-O-，或其立体异构体形式，立体异构体混合物或其药学上可接受的盐形式，它们可用作HCV NS3蛋白酶的抑制剂，以及包含它们的制药组合物和诊断试剂盒，以及将它们用于治疗病毒感染或作为测定标准或试剂的方法。
• LYSINE COMPOUNDS AND THEIR USE IN SITE- AND CHEMOSELECTIVE MODIFICATION OF PEPTIDES AND PROTEINS
  申请人：Ovaa Huib

  公开号：US20120135913A1

  公开（公告）日：2012-05-31

  The present invention concerns new thiolysine and selenolysine compounds that can be used as building blocks for peptides and proteins, providing ligation handles for site- and chemoselective modification of said peptides and proteins. In particular, the invention provides. In particular, the invention provides (the use of) the compounds 5-thiolysine (also referred to as δ-thiolysine); 4-thiolysine (also referred to as γ-thiolysine); 5-selenolysine (also referred to as δ-selenolysine) and 4-selenolysine (also referred to as γ-selenolysine). The positioning of the thiol or selenol group at the respective carbon atom allows for a very efficient intramolecular transfer reaction to take place after conjugation with a selected ligand, and the thiol or selenol group may subsequently be removed using reported procedures, thereby restoring the native lysine structure, or be used as an additional conjugation handle. The methodology is fast and gives well-defined material.

  本发明涉及新的巯基赖氨酸和硒基赖氨酸化合物，可用作肽和蛋白质的构建块，为所述肽和蛋白质的位点和化学选择性修饰提供连接手柄。具体而言，本发明提供了化合物5-巯基赖氨酸（也称为δ-巯基赖氨酸）；4-巯基赖氨酸（也称为γ-巯基赖氨酸）；5-硒基赖氨酸（也称为δ-硒基赖氨酸）和4-硒基赖氨酸（也称为γ-硒基赖氨酸）的使用。将巯基或硒基团位于相应的碳原子上，可在与所选配体共轭后发生非常高效的分子内转移反应，巯基或硒基团随后可使用已知的程序去除，从而恢复天然的赖氨酸结构，或用作额外的连接手柄。该方法快速且给出明确的材料。